• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非诺贝特及非诺贝酸在体内及肝上皮细胞培养中的代谢(作者译)

[Metabolism of fenofibrate and fenofibric acid in vivo and in cultures of liver epithelial cells (author's transl)].

作者信息

Dulery B, Hammami M, Chessebeuf M, Legendre M, Noly P, Padieu P, Maume B F

出版信息

Nouv Presse Med. 1980 Dec 22;9(49):3729-32.

PMID:7208338
Abstract

In vitro and in vivo studies using capillary column gas chromatography alone or coupled with mass spectrometry resulted in the identification of several metabolites of fenofibrate (LF 178). Fenofibric acid (LF 153) was omnipresent, being found in rats after acute, subacute and chronic administration, in human urine during chronic treatment, and in cultures of rat and human liver cells. Other metabolites were LF 433 (LF 153 benzhydrol), which increases in rats with the duration of treatment while LF 153 decreases, and LF - phenol" found in human urine. In hepatocyte cultures, fenofibric acid was predominant, but fenofibrate itself and LF 321 (LF 178 benzhydrol) were also present in addition to the above-mentioned metabolites. LF 321, however, was only found in human liver cell cultures.

摘要

单独使用毛细管柱气相色谱法或与质谱联用进行的体外和体内研究,鉴定出了非诺贝特(LF 178)的几种代谢物。非诺贝酸(LF 153)普遍存在,在大鼠急性、亚急性和慢性给药后均可发现,在慢性治疗期间的人类尿液中以及大鼠和人类肝细胞培养物中也能找到。其他代谢物包括LF 433(LF 153二苯甲醇),其在大鼠体内随治疗时间延长而增加,而LF 153则减少,以及在人类尿液中发现的“LF - 苯酚”。在肝细胞培养物中,非诺贝酸占主导地位,但除上述代谢物外,非诺贝特本身和LF 321(LF 178二苯甲醇)也存在。然而,LF 321仅在人类肝细胞培养物中发现。

相似文献

1
[Metabolism of fenofibrate and fenofibric acid in vivo and in cultures of liver epithelial cells (author's transl)].非诺贝特及非诺贝酸在体内及肝上皮细胞培养中的代谢(作者译)
Nouv Presse Med. 1980 Dec 22;9(49):3729-32.
2
The metabolism and disposition of fenofibrate in rat, guinea pig, and dog.
Drug Metab Dispos. 1988 Mar-Apr;16(2):302-9.
3
[Pharmacokinetics of fenofibrate in man (author's transl)].
Nouv Presse Med. 1980 Dec 22;9(49):3725-7.
4
The metabolism and disposition of 14C-fenofibrate in human volunteers.
Drug Metab Dispos. 1990 Jan-Feb;18(1):115-20.
5
[How does fenofibrate exert its cholesterol-lowering effect? (author's transl)].非诺贝特如何发挥其降胆固醇作用?(作者译)
Nouv Presse Med. 1980 Dec 22;9(49):3733-6.
6
[Pharmacology of fenofibrate (author's transl)].非诺贝特的药理学(作者译)
Nouv Presse Med. 1980 Dec 22;9(49):3769-73.
7
[Fenofibrate, efficacy and tolerance in long-term treatment (author's transl)].非诺贝特,长期治疗中的疗效与耐受性(作者译)
Therapie. 1981 Jul-Aug;36(4):473-6.
8
[Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].普罗布考、非诺贝特和氯贝丁酯对大鼠肝脏超微结构影响的比较研究(作者译)
Nouv Presse Med. 1980 Oct 30;9(40):3005-7.
9
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.贝特类药物对人载脂蛋白A-I转基因小鼠中人类与小鼠载脂蛋白A-I的反向调节作用
J Clin Invest. 1996 Jun 1;97(11):2408-16. doi: 10.1172/JCI118687.
10
Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.非诺贝特可预防罗格列酮诱导的ob/ob小鼠体重增加。
Int J Obes (Lond). 2005 Jul;29(7):864-71. doi: 10.1038/sj.ijo.0802943.